Chapter 18 Should the Ovaries be Removed During a Hysterectomy?

Chapter 18
Should the Ovaries be Removed During a Hysterectomy?
Michael S. Broder, MD, MSHS
Wendy C. Hsiao, BS
Introduction
In the US, bilateral salpingo-oophorectomy (BSO) at the time of hysterectomy for benign disease
is commonly done to prevent the subsequent development of ovarian cancer. Almost all BSOs (87%) are
done at time of hysterectomy [1]. Oophorectomy rates appear to have peaked recently, with 55% of
hysterectomies accompanied by the procedure in 1999 compared to 39-45% in more recent years [2, 3, 4].
Recent data show age remains the strongest predictor of elective BSO, with 40% of women 40-44 years
old, 78% of women 50-54 years old, and 68% of women 55 years or older having had BSO at
hysterectomy [5].
Despite the common practice of “risk-reducing” or prophylactic oophorectomy at the time of
hysterectomy for benign disease, an increasing body of evidence suggests removal of normal ovaries has
minimal overall benefit for those women who are not at an increased risk of breast or ovarian cancer.
Several large cohort studies suggest that while removing normal ovaries reduces the risk of ovarian
cancer to almost zero, prophylactic oophorectomy does not appear to increase overall survival. This
chapter will address the history of risk-reducing oophorectomy, assess the evidence for the practice, and
consider its appropriateness in light of recent studies.
History
The development of modern abdominal surgery and the search for safe surgical treatments for
ovarian tumors are closely intertwined. In 1806, Ephraim McDowell removed an ovarian tumor, and
made history when the patient survived. Forty-seven years later, Walter Burnham performed the first
successful hysterectomy [6]. The ensuing 100 years saw a substantial increase in oophorectomy resulting
from better anesthesia, the introduction of aseptic techniques and effective antibiotics, and the widespread
use of exogenous replacements for ovarian hormones. Advances in anesthesia and reductions in infection
increased oophorectomy indirectly by contributing to the more widespread use of hysterectomy, while the
synthetic estrogens removed a major barrier to incidental BSO: the reluctance to induce surgical
menopause and its concomitant risks. .
In the second half of the 19th century, the use of ether and chloroform allowed physicians to
experiment with surgical procedures that previously could not be attempted. In 1867, Joseph Lister
published his treatise “On the Antiseptic Principle of the Practice of Surgery”, and not long after, the
“hand-washing fool”, Ignaz Semmelweis, dramatically reduced rates of puerperal sepsis by introducing
hand-washing to Vienna General Hospital’s obstetric service. Halsted introduced the sterilized medical
glove in 1890, but even with these infection-reducing innovations, the mortality rate for hysterectomy was
30% in the late 19th century [6]. The modern antibiotic era began with mass production of penicillin
(driven by the needs of U.S. troops in World War II). By 1950, penicillin was reported to reduce
morbidity after vaginal hysterectomy. As the mortality fell, it became more appropriate to consider
1
hysterectomy for non-life threatening conditions, and in 1984 more than a third of women could expect to
have a hysterectomy by age 60 [7].
Although hysterectomy rates rose steadily in the late 20th century, rates of BSO remained fairly
constant. A multi-center study showed hysterectomy was accompanied by BSO at a rate of between 9 and
12% over the 25 years from 1928 to 1953 [8]. This began to change when, in the 1950s, a series of
publications raised concern among gynecologists about ovarian cancer in “residual” ovaries--those not
removed at hysterectomy [9, 10]. Case series of women who developed ovarian cancer years after
hysterectomy were extrapolated to calculate the number of women who could be “saved” had all such
procedures been accompanied by BSO [11, 12]. As a result, by the 1960’s, gynecologists were
enthusiastically recommending BSO at hysterectomy after age 40, or younger if childbearing was
complete [8].
The primary disadvantage of BSO before natural menopause was considered to be the
combination of symptoms caused by lack of ovarian hormones and osteoporosis. In 1941, the newly
established FDA approved DES to treat menopausal symptoms, and approval of conjugated equine
estrogens followed the year after. Several books published over the next 25 years, most notably Feminine
Forever by gynecologist Robert Wilson, depicted menopause as the enemy of youth [13]. As estrogen
therapy (ET) began to be seen as the cure for the scourge of menopause, the number of women using it to
treat menopausal symptoms rose: from about 2.5 million women in 1966 to over 4.7 million women in
1975. After unopposed estrogen was linked to endometrial cancer, the number dropped to 2.3 million in
1980. The introduction of combination estrogen/progestin therapy (E+P) negated this risk, and by 1995
10 million US women were using exogenous estrogen. A proposed cardiovascular benefit helped drive
this up to approximately 15 million by 2001 [14, 15, 16].
Following the publication of data from the Women’s Health Initiative (WHI) in 2002, faith in
hormone therapy drastically declined [17]. This large randomized placebo-controlled trial of E+P in postmenopausal women was terminated prematurely when the overall health risks were demonstrated to
exceed the benefits [18]. By 2003, fewer than 8.3 million women were taking exogenous estrogen, a level
not seen since the mid-1990s [15, 16].
With no reliable tools to screen for or prevent ovarian cancer, oophorectomy has been seen as the
best form of prevention, with hormone deprivation its primary downside. Thus, when faith in estrogen
was high, the oophorectomy rate climbed; when faith declined, so did the rate of BSO. The figure shows
this relationship. In 1965, 25% of hysterectomies in the US were accompanied by BSO. By 1975 the
proportion had increased to almost 40% [7, 19]. The percentage of hysterectomies with BSO peaked
in1999 at 55%, but by 2006 was estimated at only 36% [2, 3]. (Fig. 18.1).
Recent Evidence
Two recent large prospective cohort studies have provided new evidence concerning the benefits
and risks of BSO. These studies, together involving more than 50,000 US women, estimated the health
effects of BSO compared to ovarian conservation at hysterectomy on mortality and a variety of other
outcomes. Taken together, they represent the best evidence currently available to estimate the influence of
BSO on overall health.
The Nurses’ Health Study (NHS) is a large, prospective cohort study of female nurses aged 30-55
in 1976. In 2009, we published a study of 29,380 women enrolled in the NHS who had hysterectomy for
benign disease [21]. Of these, 55.6% had BSO and 44.4% had ovarian conservation. The mean age at
enrollment was 51 years, and the cohort consisted mostly of white women with relatively uniform
2
education, socioeconomic status, and access to health care. These women were followed for an average of
24 years, from 1976 through 2002, and they reported new diagnoses and health conditions every 2 years
by mail-in survey. Survey data were confirmed in interviews and by review of medical records. We
stratified the cohort into those < 45, 45-54, and 55 years or older at the time of hysterectomy. The study
analyzed the incidence of breast, epithelial ovarian, lung, or colorectal cancer; hip fracture; coronary heart
disease (CHD); stroke; pulmonary embolism (PE); cause-specific death for each of these causes; and
death due to all causes.
The second large cohort study was published in 2011 and followed 25,448 post-menopausal
women from the WHI Observational Study who had hysterectomy [22]. The WHI Observational Study is
a prospective cohort study of women aged 50-79 years at enrollment who were invited to participate in a
randomized controlled trial (RCT) comparing dietary modification to exogenous hormones, but who were
ineligible or declined to participate. Study participants were contacted yearly and reported any
hospitalizations or events related to outcomes of interest. Survey data were confirmed by medical record
review. Mean follow-up time was slightly less than 8 years, compared to 24 years in the NHS analysis.
Like the NHS, 56% had BSO and 44% had ovarian conservation. The mean age at enrollment was 63
years, compared to 51 in the NHS, but the cohorts were otherwise similar. Study subjects were stratified
into those < 40, 40-49, and 50 years or older at time of hysterectomy. Outcome measures included
incident ovarian, breast, lung, or colorectal cancer; hip fracture; cardiovascular events including CHD,
stroke, and total CVD events; and all-cause death. The study did not report cause-specific death. Both
studies performed separate analyses among women who did not use ET. We summarize the study results
by outcome below.
Cancer
Breast cancer
The NHS demonstrated a statistically significantly reduced risk of breast cancer in women who
had BSO compared to those who had ovarian conservation (all women, HR 0.75, 95% CI 0.68-0.84;
women < 45 years old at hysterectomy, HR 0.62, 95% CI 0.53-0.74). In women who never used ET,
BSO reduced the point estimate for breast cancer risk, but the difference was not statistically significant
(all women, HR 0.85, 95% CI 0.61-1.20; women < 50 years old at hysterectomy, HR 0.66, 95% CI 0.431.03). There was no difference in the risk of death from breast cancer between BSO and ovarian
conservation (all women, HR 0.94, 95% CI 0.70-1.26) [21].
The WHI data showed a statistically significant protective effect of BSO on breast cancer in
women < 40 at time of hysterectomy with no history of ET use (HR 0.36, 95% CI 0.14-0.95). The authors
did not attempt to estimate the risk of death from breast cancer [22]. Both studies suggest BSO reduces
breast cancer risk, particularly in younger women, but it may not reduce risk of death from breast cancer.
Power calculations suggest that if the actual reduction in mortality were equal to that observed in the NHS
(0.94), an RCT of over 400,000 patients would be required to have 80% power to detect such a difference.
(Table 18.2)
Ovarian cancer
The NHS showed that BSO statistically significantly reduced the risk of ovarian cancer in all
women (HR 0.04, 95% CI 0.01-0.09) and reduced the risk of death from ovarian cancer (all women, HR
0.06, 95% CI 0.02-0.21) [21]. In the WHI study, there was a 0.02% incidence of ovarian cancer in
women who received both BSO and hysterectomy, compared to 0.33% incidence in women with
hysterectomy alone. BSO statistically significantly reduced the risk of ovarian cancer in women who did
not use ET (0.04% vs. 0.23%) [22]. There is some evidence from other studies that hysterectomy alone
3
reduces the risk of ovarian cancer, but BSO at hysterectomy clearly reduces both the risk of ovarian
cancer and the risk of death from this disease.
Lung Cancer
BSO was associated with a statistically significantly increased risk of lung cancer (HR 1.26, 95%
CI 1.02-1.56) and an increased risk of death from lung cancer in the NHS (HR 1.31, 95% CI 1.02-1.68) in
all women. Risk of lung cancer was further increased in women who had never used ET (HR 2.09, 95%
CI 1.01-4.33) [21]. There was no association of BSO with lung cancer in the WHI study (all women, HR
0.96, 95% CI 0.72-1.27) [22]. There is no agreed-upon biological explanation of the observations from
the NHS, although some theories have been proposed [23, 24].
Total cancer
In the NHS, BSO was associated with a statistically significantly reduced risk of total cancer (all
women, HR 0.90, 95% CI 0.84-0.96), consistent with the reduction in breast and ovarian cancer. However,
the risk of death from all cancers was statistically significantly increased in all women who had BSO (HR
1.17, 95% CI 1.04-1.32) [21]. The WHI study found a similar point estimate for the risk of total cancer,
but the result was not statistically significant (all women, HR 0.96, 95% CI 0.87-1.05) [22]. The study did
not report cancer-specific mortality.
Cardiovascular Disease
In the NHS, BSO was associated with a statistically significantly increased risk of CHD (all
women, HR 1.17, 95% CI 1.02-1.35). BSO was associated with increased point estimates of risk for
stroke among all women, although the results were not statistically significant (HR 1.14, 95% CI 0.981.33). The effect of BSO on cardiovascular disease risk was greater in women who had not used ET: in
the group of never users, BSO statistically significantly increased the risk of stroke (HR 1.85, 95% CI
1.09-3.16). Women younger than 50 who did not use ET had increased risk of both CHD (HR 1.98, 95%
CI 1.18-3.32) and stroke (HR 2.19, 95% CI 1.16-4.14). BSO was associated with a statistically
significantly increased risk of death from CHD (HR 1.28, 95% CI 1.00-1.64) and an increased point
estimate of the risk of death from stroke (HR 1.11, 95% CI 0.82-1.51), although this last finding did not
reach statistical significance [21].
In contrast, the WHI study found no difference in the risk of cardiovascular disease between
women who had BSO compared to those with ovarian conservation (all women, HR 0.99, 95% CI 0.911.09). Among women who did not use ET, the point estimate for risks of CHD (HR 1.24, 95% CI 0.921.68), stroke (HR 1.31, 95% CI 0.92-1.87), and total cardiovascular disease (HR 1.05, 95% CI 0.89-1.25)
were increased, but these findings were not statistically significant. The WHI findings are limited by short
follow-up (~ 8 years), especially since CHD may take approximately 15 years to develop following
oophorectomy [22, 26].
Overall, the evidence suggests that BSO at the time of hysterectomy increases the risk of
cardiovascular disease and cardiovascular-disease-related mortality. Lack of ET use further increases risk.
Inconsistencies between studies may be due to lower power in the WHI study [22].
Hip Fracture
4
In both the NHS and WHI studies, there was no statistically significant association between BSO
and hip fracture (all women, HR 0.89, 95% CI 0.71-1.12 in the NHS; all women, HR 0.83, 95% CI 0.631.10 in the WHI), and these findings were consistent whether or not there was history of ET use [21, 22].
Survival
The NHS found that BSO statistically significantly increased all-cause mortality (all women, HR
1.12, 95% CI 1.03-1.21), related in part to the increased risk of death from lung cancer, all cancers, and
CHD. Risk of all-cause mortality was statistically significantly increased in women less than 50 at
hysterectomy who had never used ET (HR 1.40, 95% CI 1.01-1.96) [21]. The WHI study found no
statistically significant difference in mortality among all women (HR 0.98, 95% CI 0.87-1.10). In women
less than 40 who had not used ET, the point estimate for mortality was increased, but this was not
statistically significant (HR 1.15, 95% CI 0.78-1.70) [22]. Neither study reported a survival benefit for
BSO at any age or in any subgroup. (Table 18.3)
Other Evidence
While these two studies represent the largest and best-controlled studies to examine the impact of
oophorectomy compared to conservation of the ovaries at hysterectomy, other studies have addressed
various aspects of the question. A recent systematic review of the impact of BSO on CHD found
oophorectomy did not increase the risk of CHD overall, but most of the trials were low quality. The
review found no benefit of BSO [25]. A large cohort study published in 2011 investigated cardiovascular
disease risk in 184,441 hysterectomized women in the Swedish Inpatient Register, showing statistically
significantly increased risks of both CHD and stroke in women younger than 50 who had BSO at
hysterectomy compared to those who had neither hysterectomy nor BSO [27]. A retrospective cohort
study of 2,383 women in Olmsted County, MN found an increase in all-cause mortality in women < 45
who had oophorectomy, but observed no such increase in older women [28]. Using the same cohort, an
association between oophorectomy and increased risk of neurologic conditions (Parkinsonism, dementia,
and anxiety or depression) was identified, but the findings await confirmation in other populations [29,
30]. Finally, a Markov model estimated that overall mortality was increased in women who had
oophorectomy before age 65. At no age was there a survival advantage with oophorectomy [31]. 18.
Recommendations
Oophorectomy at the time of hysterectomy has become a common operation, primarily as a
prophylactic measure to reduce the risk of ovarian cancer. There are several reasons why this traditional
practice should be reconsidered for women who do not have a clearly elevated risk of breast or ovarian
cancer due to BRCA mutation or family or personal history.
First, a major driver of the increase in oophorectomy rates was the availability of exogenous
estrogen therapy. As recent studies have shown, however, encouraging long term drug therapy without
long term outcome studies is fraught with potential dangers. Fewer women are willing to begin taking
estrogen, and among those who do, the continuation rate is low. Even if women could be persuaded to
stay on therapy, long term estrogen has not been shown to lengthen life, nor does it completely mitigate
the risks of oophorectomy. Second, while oophorectomy does dramatically reduce the risk of ovarian
cancer in all women and reduces the risk of breast cancer in younger women, there is no evidence that it
prolongs life. In fact, the best available evidence suggests either a net harmful effect or, at best, a neutral
effect. Current evidence indicates this lack of overall benefit likely relates to the relatively low incidence
of ovarian cancer in contrast to the relatively common nature of CHD, the risk of which is increased with
oophorectomy.
5
The data on which these conclusions are based derive from observational studies. However, the
data supporting prophylactic oophorectomy were based on even lower quality evidence—namely,
theoretical considerations and case series. Considering the weight of the evidence, if “prophylactic
oophorectomy” was a new drug or device, regulatory agencies would be unlikely to approve it. Waiting
for evidence for RCTs before deciding whether to recommend BSO for a woman having hysterectomy
might be reasonable (although given the necessary size of such a trial, analysis of patient outcomes would
entail a long wait), but in the meantime, it might be wise to consider the admonition to “first, do no
harm.”
6
TABLES
Table 18.1
Proportion of hysterectomies accompanied by BSO
Annual no. of women using ET (estimated from number of prescription fills [15, 16])
Sources:


See Ref. 2
See Ref. 3
* See Ref. 7
●
See Ref. 8
■


▲
See Ref. 14
See Ref. 15
See Ref. 19
See Ref. 20
7
Table 18.2. Impact of Oophorectomy on Cancer Outcomesa
Hazard Ratio (95% Confidence Interval)
Breast cancer
Ovarian cancer
All cancers
Incidence
Death
Incidence
Death
Incidence
Death
0.62 (0.53-0.74)
0.74 (0.47-1.18)
0.03 (0.01-0.14)
0.06 (0.01-0.43)
0.83 (0.75-0.92)
1.08 (0.91-1.27)
0.72 (0.51-1.02)
-
-
-
0.97 (0.81-1.17)
-
0.66 (0.43-1.03)
-
-
-
-
-
0.36 (0.14-0.95)
-
-
-
0.93 (0.62-1.39)
-
1.05 (0.71-1.55)
1.28 (0.46-3.54)
0.07 (0.01-0.60)
-
1.01 (0.79-1.29)
1.50 (0.91-2.45)
1.02 (0.74-1.41)
-
-
-
1.08 (0.89-1.32)
-
1.88 (0.66-5.32)
-
-
-
-
-
0.77 (0.41-1.45)
-
-
-
0.92 (0.63-1.33)
-
0.75 (0.68-0.84)
0.94 (0.70-1.26)
0.04 (0.01-0.09)
0.06 (0.02-0.21)
0.90 (0.84-0.96)
1.17 (1.04-1.32)
0.96 (0.81-1.13)
-
-
-
0.96 (0.87-1.05)
-
0.85 (0.61-1.20)
-
-
-
-
-
0.72 (0.49-1.05)
-
-
-
0.90 (0.74-1.10)
-
Younger women
< 45 years
< 40 yearsb
No ET use,
< 50 years
old
No ET use,
< 40 years
oldb
Older women
≥ 55 years
old
≥ 50 years
oldb
No ET use,
≥ 50 years
old
No ET use,
≥ 50 years
oldb
All women
All ages
b
All ages
No ET use,
all ages
No ET use,
all agesb
a
b
See Ref. 21, unless otherwise noted
See Ref. 22
8
Table 18.3. Impact of Oophorectomy on Non-Cancer Health Outcomesa
Hazard Ratio (95% Confidence Interval)
Incidence
Death
Incidence
Death
All-Cause
Mortality
Death
1.26 (1.04-1.54)
1.14 (0.81-1.61)
1.19 (0.96-1.49)
0.85 (0.54-1.34)
1.06 (0.95-1.18)
< 40 years
No ET use,
< 50 years old
No ET use,
< 40 years oldb
Older women
0.98 (0.72-1.35)
-
1.13 (0.81-1.58)
-
0.90 (0.72-1.13)
1.98 (1.18-3.32)
-
2.19 (1.16-4.14)
-
1.40 (1.01-1.96)
1.33 (0.77-2.30)
-
1.44 (0.78-2.65)
-
1.15 (0.78-1.70)
≥ 55 years old
1.31 (0.73-2.36)
1.51 (0.86-2.64)
2.26 (0.85-5.95)
1.14 (0.85-1.52)
≥ 50 years oldb
No ET use,
≥ 50 years old
No ET use,
≥ 50 years oldb
All women
1.02 (0.74-1.41)
4.10 (0.4141.06)
-
0.98 (0.68-1.41)
-
1.07 (0.84-1.35)
0.70 (0.34-1.44)
-
1.21 (0.48-3.00)
-
2.05 (0.87-4.79)
1.00 (0.56-1.78)
-
1.37 (0.62-3.00)
-
0.97 (0.62-1.52)
1.17 (1.02-1.35)
1.28 (1.00-1.64)
1.14 (0.98-1.33)
1.11 (0.82-1.51)
1.12 (1.03-1.21)
1.00 (0.85-1.18)
-
1.04 (0.87-1.24)
-
0.98 (0.87-1.10)
1.42 (0.93-2.16)
-
1.85 (1.09-3.16)
-
1.20 (0.91-1.57)
1.24 (0.92-1.68)
-
1.31 (0.92-1.87)
-
0.99 (0.80-1.23)
CHD
Stroke
Younger women
< 45 years
b
All ages
b
All ages
No ET use, all
ages
No ET use, all
agesb
a
b
See Ref. 21, unless otherwise noted
See Ref. 22
9
REFERENCES
1.
Melton LJ 3rd, Bergstralh EJ, Malkasian GD, et al. Bilateral oophorectomy trends in Olmsted
County, Minnesota, 1950-1987. Epidemiology. 1991 Mar;2(2):149-52.
2.
Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. Hysterectomy surveillance—United States, 19941999. MMWR Surveill Summ. 2002;51(SS05):1-8.
3.
Asante A, Whiteman MK, Kulkarni A, et al. Elective oophorectomy in the United States: trends
and in-hospital complications, 1998-2006. Obstet Gynecol. 2010 Nov;116(5):1088-95.
4.
Lowder JL, Oliphant SS, Ghetti C, et al. Prophylactic bilateral oophorectomy or removal of
remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet
Gynecol. 2010 Jun;202(6):538.e1-9.
5.
Jacoby VL, Vittinghoff E, Nakagawa S, et al. Factors associated with undergoing bilateral
salpingo-oophorectomy at the time of hysterectomy for benign conditions. Obstet Gynecol. 2009
Jun;113(6):1259-67.
6.
Rock JA. Historical development of pelvic surgery. In: Thompson JD, Rock JA, eds. Te Linde’s
Operative Gynecology. 7th ed. Philadelphia, PA: J. B. Lippincott Company; 1992:1.
7.
Pokras R, Hufnagel VG. Hysterectomy in the United States, 1965-84. Am J Public Health. 1988
Jul;78(7):852-3.
8.
Randall CL, Paloucek FP. The frequency of oophorectomy at the time of hysterectomy: trends
in surgical practice, 1928-1953. Am J Obstet Gynecol. 1968 Mar 1;100(5):716-26.
9.
Christ JE, Lotze EC.
The residual ovary syndrome. Obstet Gynecol. 1975 Nov;46(5):551-6.
10.
Speert H. Prophylaxis of Ovarian Cancer. Ann Surg. 1949 Apr;129(4):468-75.
11.
Grundsell H, Ekman G, Gullberg B, et al. Some aspects of prophylactic oophorectomy and
ovarian carcinoma. Ann Chir Gynaecol. 1981;70(1):36-42.
10
12.
Sightler SE, Boike GM, Estape RE, et al. Ovarian cancer in women with prior hysterectomy: a
14-year experience at the University of Miami. Obstet Gynecol. 1991 Oct;78(4):681-4.
13.
Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines
and regimens approved by the US Food and Drug Administration. Am J Med. 2005 Dec 19;118
Suppl 12B:64-73.
14.
Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns
over time. Obstet Gynecol. 1985 Mar;65(3):441-6.
15.
Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy:
annual trends and response to recent evidence. JAMA. 2004 Jan 7;291(1):47-53.
16.
Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in
the United States, 1982-1992. Obstet Gynecol. 1995 Jan;85(1):6-10.
17.
Wegienka G, Havstad S, Kelsey JL. Menopausal hormone therapy in a health maintenance
organization before and after women's health initiative hormone trials termination. J Womens
Health (Larchmt). 2006 May;15(4):369-78.
18.
Writing Group for the Women's Health Initiative Investigators, Rossouw JE, Anderson GL, et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results
From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul
17;288(3):321-33.
19.
Pokras R, Hufnagel VG. Hysterectomies in the United States. Vital Health Stat. 1987;13(92):1-32.
20.
Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through
June, 2003. Pharmacoepidemiol Drug Saf. 2005 Mar;14(3):171-6.
21.
Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and
long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009 May;113(5):102737.
22.
11
Jacoby VL, Grady D, Wactawski-Wende J, et al. Oophorectomy vs ovarian conservation with
hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative
Observational Study. Arch Intern Med. 2011 Apr 25;171(8):760-8.
23.
Brinton LA, Gierach GL, Andaya A, et al. Reproductive and hormonal factors and lung cancer
risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2011
May;20(5):900-11.
24.
Liu Y, Inoue M, Sobue T, et al. Reproductive factors, hormone use and the risk of lung cancer
among middle-aged never-smoking Japanese women: a large-scale population-based cohort
study. Int J Cancer. 2005 Nov 20;117(4):662-6.
25.
Jacoby VL, Grady D, Sawaya GF. Oophorectomy as a risk factor for coronary heart disease.
Am J Obstet Gynecol. 2009 Feb;200(2):140.e1-9.
26.
Parrish HM, Carr CA, Hall DG, et al. Time interval from castration in premenopausal women to
development of excessive coronary atherosclerosis. Am J Obstet Gynecol. 1967 Sep
15;99(2):155-62.
27.
Ingelsson E, Lundholm C, Johansson AL, et al. Hysterectomy and risk of cardiovascular
disease: a population-based cohort study. Eur Heart J. 2011 Mar;32(6):745-50.
28.
Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in
premenopausal women: a population-based cohort study. Lancet Oncol. 2006 Oct;7(10):821-8.
29.
Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or
dementia in women who underwent oophorectomy before menopause. Neurology. 2007 Sep
11;69(11):1074-83.
30.
Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who
underwent oophorectomy before menopause. Neurology. 2008 Jan 15;70(3):200-9.
31.
Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for
benign disease. Obstet Gynecol. 2005 Aug;106(2):219-26.
12